Drospirenone-only pill

Phase 2Small molecule

UUniversity of Colorado, Denver

Drospirenone-only pill is one of 36 small molecule programs targeting Contraception. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ContraceptionActive, not recruiting

ContraceptionPhase 2

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Contraception

#DrugCompanyPhaseTrials

Carbocaine

Pfizer

Phase 3

1 2

Depo-Provera

Eli Lilly

Phase 3

—3

Feldene

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 4

Estradiol Valerate

Yasmin

1 6

Mirena

Bayer

Phase 3

4 7

Opill

LLaboratoire français de Fractionnement et de Biotechnologies

Phase 3

1 8

Norethindrone Acetate

WWatson Pharmaceuticals

Phase 3

2 9

Marvelon

Bayer

Phase 3

1 10

Levonorgestrel and Ethinyl Estradiol

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Contraception1 trial

Drospirenone-only Pill as Emergency Contraception

Unknown status·UUniversity of Colorado, Denver·Phase 2·NCT05675644·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drospirenone-only pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drospirenone-only pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drospirenone-only pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Colorado, Denver company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Colorado, Denver

Drospirenone-only pill

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Contraception1 trial

References

Drug Info

Quick Facts

Related News